# MIRAI SOUZOU

> MIRAI SOUZOU is a VC fund in Tokyo backing Manufacturing and Robotics. See 52 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 52
- Last investment: Aug 2026
- Lead investor: 25%
- Fund size: $549M
- Last fund: Sep 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mirai-sozou-kikou/
- Website: http://miraisozo.co.jp/
- Facebook: https://www.facebook.com/miraisozokiko/

MIRAI SOUZOU is a VC fund in Tokyo focused on Manufacturing and Robotics. MIRAI SOUZOU operates as a venture capital firm that invests in institutional lookup and supporting projects. The Company invests in institutional research and development supporting projects, medicine, agriculture, ocean field, and other industries. Innovations and Future Creation conducts businesses in Japan.

## Contacts

5 contacts available for MIRAI SOUZOU. Shizune tracks 3 team members at MIRAI SOUZOU. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/innovations-and-future-creation?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.3M–$100M |
| Series B | $938k–$184M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 13 | 25% |
| Robotics | 8 | 15% |
| Software | 8 | 15% |
| Information Technology | 6 | 12% |
| Artificial Intelligence | 6 | 12% |

88 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 12 | 23% |
| Series A | 11 | 21% |
| Series B | 10 | 19% |
| Seed | 9 | 17% |
| Venture - Series Unknown | 2 | 4% |

10 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daisuke Kaneko | Co-Founder & Director | 4 | https://shizune.co/investors/profile/daisuke-kaneko |
| Yumiko Nagatsuma | Partner | 2 | https://shizune.co/investors/profile/yumiko-nagatsuma |
| Yuyuki Okada | President and CEO | 1 | https://shizune.co/investors/profile/yuyuki-okada |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Equitas Medical Co. | Equitas Medical provides management support for clinics, including operational improvement, strategic planning, recruitment, digital transformation, and back-office administration. It supports business succession for clinic owners by providing transition options intended to maintain patient and staff continuity. The company also promotes healthcaredigital transformation through AI, cloud services, remote-care tools, hospital real-world data use, and medical department digitalization. Its services are intended for healthcare professionals, clinic owners, and healthcare organizations. | $383.4K | Seed | Aug 03, 2026 |  |
| Equitas Medical Co. | Equitas Medical provides management support for clinics, including operational improvement, strategic planning, recruitment, digital transformation, and back-office administration. It supports business succession for clinic owners by providing transition options intended to maintain patient and staff continuity. The company also promotes healthcaredigital transformation through AI, cloud services, remote-care tools, hospital real-world data use, and medical department digitalization. Its services are intended for healthcare professionals, clinic owners, and healthcare organizations. | $383.4K | Seed | Aug 03, 2026 |  |
| Varinos | Varinos is a clinical laboratory contract analysis company that is a partner of medical institutions. Varinos provides genomic testing development and contract analysis services using the latest technology, the next-generation sequencer. | $7.9M | Series D | May 12, 2026 |  |
| ElevationSpace | ElevationSpace offers high quality & well equipped workspaces giving tenants a nurturing environment . | $7.5M | Series B | Sep 17, 2025 |  |
| Metagen Therapeutics | Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis,immuno-oncology, and neurodegenerative disease. Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access. | $15.7M | Series B | Sep 08, 2025 |  |
| Logomix | Logomix Inc is a mammalian cellular genome architect startup. Logomix proprietary platform, Geno-Writing™, technology integrates large-scale (Mb) human genome-writing technologies and providing genetically architected versatile human cells and/or downsized cells and microbes for drug development and cell & gene therapy area.Majority ofthe cell engineering companies are currently focused on optimization of gene clusters by automatic high throughput system however, Logomix’s Geno-Writing™ provides the required tools for dealing with mammalian or complex genomes. Logomix works with partners by providing new biology-based solutions to co-create business and social values on Geno-Writing™ platform Current Focus Area includes: 1. Human Health & Therapeutics 2. Biomaterials & Chemicals 3. Agriculture & EnvironmentLogomix has 11 ongoing collaborative research partnerships. Currently Logomix is specifically looking for industry partners to address unmet needs in neurodegenerative disease areas. | $18.8M |  | Jul 30, 2025 |  |
| FLUX | FLUX provide “FLUX Header Bidding Solution” that creates fair competition opportunities and significantly increases advertising revenue within the header bidding server, ad requests are sent to SSPs and ad exchanges all at once, so it is possible to have a pure price competition without prioritization, and to determine the highest bid amount andvalue of the advertising space. I can. Then, the price of the highest bid ad in the header bidding and the ad set in the ad server are competed, and the ad with the higher bid is delivered. | $6.3M | Series B | Jun 03, 2025 |  |
| ASEMtech | ASEMtech is a technology company that specializes in research, development, sales, and leasing of medical equipment via the ASEM method. | $1.7M | Series A | Apr 01, 2025 |  |
| Instalimb | Instalimb is the world's first 3D printing prosthesis business. It uses advanced 3D printing, 3D-CAD, and machine-learning technologies to produce affordable, high-quality prosthetic legs. By integrating these tools into its manufacturing process, the company delivers reliable and low-cost 3D-printed prosthetics and orthotics. | $7.3M | Series B | Mar 26, 2025 |  |
| ARCS | ARCS specializes in developing assisted reproductive medical devices using robotics and artificial intelligence technology. | $3.4M | Seed | Jan 20, 2025 |  |

10 of 52 investments shown.

## Co-investors
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund, 10 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 8 deals together
- [UTokyo Innovation Platform](https://shizune.co/investors/profile/utokyo-innovation-platform) — VC Fund, 7 deals together
- [JAFCO](https://shizune.co/investors/profile/jafco-co-ltd) — VC Fund, 6 deals together
- [Incubate Fund](https://shizune.co/investors/profile/incubate-fund) — VC Fund, 5 deals together
- [Deepcore](https://shizune.co/investors/profile/deepcore) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Manufacturing Investors in Japan](https://shizune.co/investors/manufacturing-investors-japan)
- [Manufacturing VC Funds in Japan](https://shizune.co/investors/manufacturing-vc-funds-japan)
- [Climate Investors in Japan](https://shizune.co/investors/climate-investors-japan)
- [Health Care Investors in Japan](https://shizune.co/investors/health-care-investors-japan)
- [Health Care VC Funds in Japan](https://shizune.co/investors/health-care-vc-funds-japan)
- [Artificial intelligence Investors in Japan](https://shizune.co/investors/artificial-intelligence-investors-japan)

## FAQ

### What does MIRAI SOUZOU invest in?

MIRAI SOUZOU invests primarily in Manufacturing, Robotics and Software startups, most often at Funding Round and Series A stage. Most of the 52 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is MIRAI SOUZOU's check size?

MIRAI SOUZOU typically joins rounds of $2.3M–$100M at Series A and $938k–$184M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds MIRAI SOUZOU participates in.

### How do I contact MIRAI SOUZOU?

Public channels for MIRAI SOUZOU include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at MIRAI SOUZOU?

The team at MIRAI SOUZOU includes Daisuke Kaneko (Co-Founder & Director), Yumiko Nagatsuma (Partner) and Yuyuki Okada (President and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co